3rd Quarter - Report

PODESTA GROUP, INC. for COVIDIEN

Firm
Client
Income
$50,000
Expenses
—

What was lobbied

5 issue areas, each in the filer's own words, with who lobbied on it and where.

Budget/Appropriations BUD

FY 2012 appropriations legislation.

LobbyistCovered position, as disclosed
ARANTHAN JONES —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Pharmacy PHA

Issues involving controlled substances and pain and addiction drugs. Issues related to acetaminophen.

LobbyistCovered position, as disclosed
DANIELE BAIERLEIN —
ARANTHAN JONES —
STEPHEN NORTHRUP —
ANTHONY PODESTA —
THOMAS B SPARKMAN —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Taxation/Internal Revenue Code TAX

International taxation on direct foreign investment.

LobbyistCovered position, as disclosed
DANIELE BAIERLEIN —
ARANTHAN JONES —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Copyright/Patent/Trademark CPT

H.R. 1249 / S. 23, America Invents Act.

LobbyistCovered position, as disclosed
ARANTHAN JONES —
THOMAS B SPARKMAN —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: S. 23 (112th), H.R. 1249 (112th)

Health Issues HCR

Patient Protection and Affordable Care Act implementation. S. 99, American Medical Isotopes Production Act of 2011; issues related to nuclear medicine. FDA approval process/510(k). Medical device tax.

LobbyistCovered position, as disclosed
DANIELE BAIERLEIN —
ARANTHAN JONES —
STEPHEN NORTHRUP —
THOMAS B SPARKMAN —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: S. 99 (112th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.